Oroxin B (30 mg/kg, i.p., 28 days) induces malignant lymphoma cell ER stress, and inhibits tumor growth in human lymphoma cell (Raji cell) xenograft model[2].
Oroxin B (160 μM of 10 μL, injected into the knee joints of mice) protects articular cartilage in destabilized medial meniscus (DMM) induced mice OA[3].
Oroxin B (200 mg/kg/day, oral gavage) relieves hepatic inflammation and inhibits MAFLD progression in HFD-fed rats[4].
| Animal Model: | Human lymphoma cell (Raji cell) xenograft model[2] |
| Dosage: | 30 mg/kg |
| Administration: | i.p., 28 days |
| Result: | Induced malignant lymphoma cell ER stress.
Inhibited tumor growth.
Prolonged overall survival of tumor-bearing mice. |
| Animal Model: | HFD-fed rats[4] |
| Dosage: | 200 mg/kg/day |
| Administration: | oral gavage |
| Result: | Reduced the levels of plasma lipids, LPS, IL-6, and TNF-α.
Inhibited liver fibrosis by reducing collagen deposition.
|
